The stock of Altimmune Inc (ALT) has seen a 12.82% increase in the past week, with a -7.12% drop in the past month, and a -6.01% decrease in the past quarter. The volatility ratio for the week is 5.86%, and the volatility levels for the past 30 days are at 6.09% for ALT. The simple moving average for the past 20 days is 6.10% for ALT’s stock, with a -11.96% simple moving average for the past 200 days.
Is It Worth Investing in Altimmune Inc (NASDAQ: ALT) Right Now?
The stock has a 36-month beta value of 0.07. Opinions on the stock are mixed, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALT is 70.48M, and at present, short sellers hold a 31.78% of that float. On October 16, 2024, the average trading volume of ALT was 2.31M shares.
ALT) stock’s latest price update
The stock of Altimmune Inc (NASDAQ: ALT) has increased by 9.49 when compared to last closing price of 6.43. Despite this, the company has experienced a 12.82% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-15 that GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple classes of atherogenic and cardio-inflammatory lipids in subjects treated with pemvidutide will be presented in a poster session at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases (AASLD) in San Diego, CA taking place November 15-19, 2024. The data were derived from Altimmune’s 12-week Phase 1b randomized, placebo-controlled study in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD), a precursor to the more serious metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed enrollment in a Phase 2b efficacy trial of pemvidutide in patients with biopsy-confirmed F2/F3 MASH, with topline data expected in the second quarter of 2025.
Analysts’ Opinion of ALT
Goldman, on the other hand, stated in their research note that they expect to see ALT reach a price target of $13. The rating they have provided for ALT stocks is “Neutral” according to the report published on January 24th, 2024.
Goldman gave a rating of “Neutral” to ALT, setting the target price at $6 in the report published on March 22nd of the previous year.
ALT Trading at 5.78% from the 50-Day Moving Average
After a stumble in the market that brought ALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.56% of loss for the given period.
Volatility was left at 6.09%, however, over the last 30 days, the volatility rate increased by 5.86%, as shares sank -7.00% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.48% upper at present.
During the last 5 trading sessions, ALT rose by +12.82%, which changed the moving average for the period of 200-days by -39.41% in comparison to the 20-day moving average, which settled at $6.64. In addition, Altimmune Inc saw -37.42% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALT starting from Drutz David, who sale 16,011 shares at the price of $6.90 back on Aug 19 ’24. After this action, Drutz David now owns 41,958 shares of Altimmune Inc, valued at $110,547 using the latest closing price.
Stock Fundamentals for ALT
Current profitability levels for the company are sitting at:
- -237.86 for the present operating margin
- -48.99 for the gross margin
The net margin for Altimmune Inc stands at -247.79. The total capital return value is set at -0.61. Equity return is now at value -63.29, with -56.83 for asset returns.
Based on Altimmune Inc (ALT), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -38.39. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 3891.32.
Currently, EBITDA for the company is -83.03 million with net debt to EBITDA at 0.58. When we switch over and look at the enterprise to sales, we see a ratio of 1088.1. The receivables turnover for the company is 0.14for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.30.
Conclusion
To sum up, Altimmune Inc (ALT) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
